<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03837756</url>
  </required_header>
  <id_info>
    <org_study_id>TITAN-001</org_study_id>
    <secondary_id>2018-001165-16</secondary_id>
    <secondary_id>AGR-2016-8833</secondary_id>
    <nct_id>NCT03837756</nct_id>
  </id_info>
  <brief_title>Combining TLR9 Agonist With bNAbs for Reservoir Reduction and Immunological Control of HIV</brief_title>
  <acronym>TITAN</acronym>
  <official_title>Combining a TLR9 Agonist With Broadly Neutralizing Antibodies for Reservoir Reduction and Immunological Control of HIV Infection: An Investigator-initiated Randomized, Placebo-controlled, Phase IIa Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Peter Doherty Institute for Infection and Immunity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety and efficacy of lefitolimod and 3BNC117/10-1074
      in HIV-1-infected individuals on ART and during ATI as intervention to reduce the HIV-1
      reservoir
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized 1:1:1:1 in a blinded fashion to receive:
Arm A: Placebo and Placebo Arm B: Lefitolimod and Placebo Arm C: Placebo and 3BNC117+10-1074 Arm D: Lefitolimod and 3BNC117+10-1074</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The participant and all study personnel who directly interact with study participants are blinded to study arm designation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time to re-initiation of cART during analytical treatment interruption (ATI)</measure>
    <time_frame>Up to 26 weeks.</time_frame>
    <description>Time from date of cART cessation to the date of the last of three consecutive plasma HIV-1 RNA measurements &gt;10,000 copies/mL, CD4 cell count &lt;350 on two consecutive measurements, or end of ATI (i.e. 26 weeks after cessation of cART) - whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability assessment measured by AEs, Adverse Reactions (ARs), SAEs,</measure>
    <time_frame>Duration of the study</time_frame>
    <description>Subject who receives at least one dose of the IMP(s) will be included in the evaluation for safety, measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs) and (SUSAR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma HIV RNA doubling time</measure>
    <time_frame>Duration of ATI (up to 26 weeks)</time_frame>
    <description>Plasma HIV RNA doubling time from first measurement &gt;50 copies/mL to first measurement &gt;1,000 copies/mL during the analytical treatment interruption (plasma HIV RNA measured by standard clinical assays, e.g. Cobas TaqMan; Lower limit of quantitation 20 copies/mL)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Arm A: Placebo/Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This arm will receive placebo (sterile saline) for both Lefitolimod and 3BNC117 + 10-1074.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Lefitolimod/Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive Lefitolimod and placebo (sterile saline) for 3BNC117 + 10-1074.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C: Placebo/3BNC117 + 10-1074</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive 3BNC117 + 10-1074 and placebo (sterile saline) for Lefitolimod.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D: Lefitolimod/3BNC117 + 10-1074</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm will receive both Lefitolimod and 3BNC117 + 10-1074.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Arm A: Placebo/Placebo</arm_group_label>
    <arm_group_label>Arm B: Lefitolimod/Placebo</arm_group_label>
    <arm_group_label>Arm C: Placebo/3BNC117 + 10-1074</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lefitolimod</intervention_name>
    <description>A TLR9 agonist administered s.c. once weekly for 8 weeks.</description>
    <arm_group_label>Arm B: Lefitolimod/Placebo</arm_group_label>
    <arm_group_label>Arm D: Lefitolimod/3BNC117 + 10-1074</arm_group_label>
    <other_name>MGN1703</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3BNC117 and 10-1074</intervention_name>
    <description>Broadly neutralizing antibodies against HIV env administered two times with a 3 week interval.</description>
    <arm_group_label>Arm C: Placebo/3BNC117 + 10-1074</arm_group_label>
    <arm_group_label>Arm D: Lefitolimod/3BNC117 + 10-1074</arm_group_label>
    <other_name>RUhumab-001 and RUhumab-002</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection

          -  Adults age 18-65 years

          -  On ART for a minimum of 18 months.

          -  CD4+ T cell count &gt;500 at screening

          -  HIV-1 RNA plasma level of &lt; 50 copies/mL by standard assays for at least 15 months (a
             single viral load measurement &gt; 50 but &lt; 500 copies/mL during this time period is
             allowable).

          -  Able to give informed consent

          -  Viral reservoir sensitivity to 3BNC117 and 10-1074. (Sensitivity of the viral
             reservoir to neutralization by 3BNC117 and 10-1074 will be tested following the
             screening visit (i.e. prior to randomization)).

        Exclusion Criteria:

          -  Any significant acute medical illness requiring hospitalization in the past 4 weeks

          -  Any evidence of an active AIDS-defining opportunistic infection

          -  Any condition that, in the Investigator's opinion, will prevent adequate compliance
             with study therapy

          -  The following laboratory values at screening, the values can be repeated within the
             screening period, but test results must be available before baseline (Day 0) and
             checked for eligibility: Hepatic transaminases (AST or ALT) ≥3 x upper limit of normal
             (ULN) // Serum total bilirubin ≥3 ULN // Estimated glomerular filtration rate (eGFR)
             ≤50 mL/min (based on serum creatinine) // Platelet count ≤100 x109/L // Absolute
             neutrophil count ≤1x109/L

          -  Hepatitis B or C infection

          -  History of: Malignancy, excluding non-melanoma skin cancers, or organ transplantation

          -  Receipt of strong immunosuppressive or systemic chemotherapeutic agents within 28 days
             prior to study entry

          -  Known resistance to &gt;2 classes of ART

          -  Known hypersensitivity to the components of lefitolimod, 3BNC117, 10-1074 or their
             analogues

          -  Pre-existing autoimmune or antibody-mediated diseases

          -  Women who are pregnant or breastfeeding, or unwilling/ unable to use an acceptable
             method of contraception (if of child bearing potential)

          -  Males or females who are unwilling or unable to use barrier contraception during
             sexual intercourse until plasma HIV-1 RNA is undetectable using standard assays
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole S Søgaard, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ole S Søgaard, MD PhD</last_name>
    <phone>+45 78452842</phone>
    <email>olesoega@rm.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jesper F Højen, MD</last_name>
    <phone>+45 40459718</phone>
    <email>jephns@rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dept. of Internal Medicine, University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam M Spivak, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital and Monash University</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Lewin, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas A Rasmussen, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dept. of Infectious Diseases, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Nielsen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Infectious Diseases, Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesper F Højen, MD</last_name>
      <phone>+45 40459718</phone>
      <email>jephns@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Infectious Diseases, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Gerstoft, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Infectious Diseases, Amager and Hvidovre Hospitals</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Benfield, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dept. of Infectious Diseases, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isik S. Johansen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual deidentified participant data (including data dictionaries) will be shared following the publication of the primary and secondary endpoints as outlined in this protocol. Data to be shared includes deidentified data points in published, peer-reviewed articles. Additional, related documents will also be available (study protocol, informed consent form, statistical analysis plan).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will become available following publication of the specific dataset with no planned end date.</ipd_time_frame>
    <ipd_access_criteria>Access to the data sharing will be given to researchers who provide a methodologically sound proposal for any type of analysis and requires IRB/Ethics committee approval (if applicable). Proposal should be addressed to olesoega@rm.dk</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

